Status: Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Apr 5, 2023Locations: 1
Eligibility criteria
Age: 18 Years and older [+5]
Stage I and stage IV NSCLC; [+11]